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Abstract
Rationale: Preeclampsia is a devastating medical complication of pregnancy which leads to maternal and fetal morbidity
and mortality. While the etiology of preeclampsia is unclear, human and animal studies suggest that excessive circulating
levels of soluble fms-like tyrosine-kinase-1 (sFlt-1), an alternatively spliced variant of VEGF-receptor1, contribute to the signs
and symptoms of preeclampsia. Since sFlt-1 binds to heparin and heparan sulfate proteoglycans, we hypothesized that the
anticoagulant heparin, which is often used in pregnancy, may interfere with the levels, distribution and elimination of sFlt-1
in vivo.
Objective: We systematically determined serum and urine levels of angiogenic factors in preeclamptic women before and
after administration of low molecular weight heparin and further characterized the interaction with heparin in biochemical
studies.
Methods and Results: Serum and urine samples were used to measure sFlt-1 levels before and after heparin administration.
Serum levels of sFlt-1 increased by 25% after heparin administration in pregnant women. The magnitude of the increase in
circulating sFlt-1 correlated with initial sFlt-1 serum levels. Urinary sFlt-1 levels were also elevated following heparin
administration and levels of elimination were dependent on the underlying integrity of the glomerular filtration barrier.
Biochemical binding studies employing cation exchange chromatography revealed that heparin bound sFlt-1 had
decreased affinity to negatively charged surfaces when compared to sFlt-1 alone.
Conclusion: Low molecular weight heparin administration increased circulating sFlt1 levels and enhanced renal elimination.
We provide evidence that both effects may be due to heparin binding to sFlt1 and masking the positive charges on sFlt1
protein.
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Introduction
In preeclampsia, generalized endothelial dysfunction leads to a
severe disorder resulting in proteinuria, hypertension, progressive
edema, headaches, seizures and severe neurologic and hepatic
complications [1]. Proteinuria and hypertension after the 20
th
week of gestation are the clinical hallmarks of the condition and
used for making the clinical diagnosis of preeclampsia. Recent
studies suggest, that circulating anti-angiogenic substances such as
a soluble splice variant of the VEGF-receptor Flt-1 (sFlt-1) and a
soluble form of the TGF-b-receptor Endoglin, soluble endoglin
(sEng) act in concert to induce endothelial dysfunction and the
maternal syndrome of preeclampsia [2–4]. Importantly, serum
levels of these anti-angiogenic substances precede the clinical signs
of preeclampsia by 5–6 weeks [4,5] suggesting that targeting these
pathways may be useful for treating or preventing this disorder.
During the last five years, several studies have used commer-
cially available ELISA assays to evaluate the plasma or serum
levels of pro- and anti-angiogenic factors for both diagnosis and
prediction of preeclampsia [6]. In particular, determination of sFlt-
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and early diagnosis of preeclampsia [4,7–12]. Automated assays to
measure sFlt-1 and PlGF are now available and allow for
expeditious routine screening of preeclampsia in an in-patient
and out-patient setting [12–14].
However, very little is known about sFlt-1 kinetics and potential
serum or plasma interfering factors and medical conditions that
may influence sFlt-1 levels and elimination. Recent reports
indicated that acute administration of high doses of heparin may
lead to increased plasma levels of sFlt-1 up to 50-fold [15,16]. This
is of particular interest as the administration of heparin is often
used in patients with thrombophilia, who are at risk for
preeclampsia and also hospitalized pregnant patients to prevent
DVTs (deep venous thrombosis) [17–23]. In contrast to other
reports, Rosenberg and colleagues reported that heparin did not
affect sFlt1 mRNA expression, or synthesis from trophoblast tissue
[24,25]. In their studies, Rosenberg et al. did not specifically
investigate shedding or proteolytic cleavage. However, other
groups have suggested that the increased levels of circulating
sFlt-1 are likely due to heparin-mediated mobilization of sFlt-1
from heparin sulfate proteoglycans present on cell surface or in the
extracellular matrix [15,16].
We performed serial measurements of sFlt-1 and PlGF serum
levels in 11 patients with suspected preeclampsia who received
daily weight adjusted low molecular weight heparin (LMWH) for
DVT-prophylaxis to investigate the influence of heparin admin-
istration on the diagnostic assays of sFlt-1 and PlGF. In addition
we analyzed urinary excretion of sFlt-1 in the presence and
absence of heparin to learn about potential routes and modalities
of sFlt-1-elimination.
Methods
Patient population
We enrolled 11 patients between 18 and 45 years of age
between April 2011 and June 2012 who were admitted to the
University Hospital Cologne with suspected or clinically evident
preeclampsia and who received subcutaneous low molecular
weight heparin (0,5 mg enoxaprin per kg bodyweight daily) for
DVT prophylaxis. Protocols were reviewed and approved by the
ethics committee of the University Hospital Cologne (protocol
number 10–238). Written informed consent was obtained from all
participants. Gestational age was estimated by menstrual history
and ultrasonography. Preeclampsia was defined as new onset of
hypertension .140/90 and proteinuria .0.3 g protein/g creat-
inine in spot urine samples or total protein excretion .300 mg
protein/24 hrs. HELLP syndrome (hemolysis elevated liver
enzymes, low platelets) was defined according to established
criteria [26].
Blood and urine sampling
Blood and urine samples were drawn 2 hrs before administra-
tion of enoxaparin-sodium, at the time of subcutaneous enox-
aparin injection and 2 hrs, as well as 12 hrs after LMWH (Figure
S1). Blood samples were obtained by venipuncture from the
cubital vein using serum separation tubes. After 10 min centrifu-
gation at 1.200 rcf in an Eppendorf 5810R swinging bucket
centrifuge samples were analysed within 2 hrs after the blood
draws, and remaining sample was stored at 280uC. Urine samples
were obtained by the clean catch method as spot urine samples.
Samples were spun at 600 rcf for 10 min, the supernatant was
analysed directly, and remaining sample was stored at 280uC.
Other parameters were assessed as per standard protocols of the
University Hospital Cologne.
sFlt-1 and PlGF measurements
Serum levels of sFlt-1 and PlGF were determined by using the
ElecsysH assays (Roche) as previously described [12]. To
determine urinary sFlt-1, we employed the QuantikineH human
sFlt-1 ELISA (R&D) as described elsewhere [27]. For in vitro
experiments enoxaprin was spiked into pre-treatment serum
samples at a final concentration of 10 mg/l. The samples were
then analyzed with the ElecsysH assays.
Velocity gradient centrifugation
A 2 ml discontinuous sucrose gradient (40–5%) was layered on
top of a 60% sucrose cushion in an ultracentrifuge tube (Beckman,
Fullerton, CA). Serum was diluted to equal parts with TBS buffer,
added on top of the gradient, and subjected to centrifugation for
22 h at 215,0006g at 4uC in a Beckman SW-60Ti rotor. After
centrifugation 22 fractions (200 ml each) were collected, and
analyzed by SDS/PAGE. Flt-1 specific monoclonal antibody
(R&D) was used for immunoblot.
Affinity purification of serum samples
Serum purification consisted of a cation exchange chromatog-
raphy step and was performed using the Mono S HR 5/5 column
(Amersham Bioscience). Gradient separation was performed on an
FPLC system (A ¨kta, GE Healthcare) using a buffer A (50 mmol/l
Tris, pH 7.3) and a buffer B (50 mmol/l Tris, pH 7.3, 1 mol/l
NaCl). Serum samples were diluted 1:1 with buffer A and loaded
in a total volume of 1 ml on the pre-equilibrated column (Flow
rate: 2 ml/min, 11% B). Serum fractions were separated using an
increasing gradient of buffer B (11 to 100% over 30 ml). Fractions
were collected during all purification steps and stored at 220uC
upon analysis. All chromatography steps were performed at 4uC
and all different serum samples were analyzed using the same
buffers and an automated chromatography method allowing
identical separation conditions.
Statistical analysis
Continuous variables were analyzed by Student’s t-test and
regression analysis was performed using logistic regression
techniques using GraphPad Prism version 4.00 (GraphPad
Software, San Diego, CA). All P values were two-tailed, and a P
value,0.05 was considered statistically significant.
Results
We studied 11 patients admitted with suspected or established
preeclampsia between 27 to 38 weeks of gestation, who were
receiving low molecular weight heparin. Patient characteristics
and laboratory values upon admission are outlined in Table 1.I n
the study blood and urine samples were drawn 2 hrs before
administration of LMWH (enoxaparin-sodium), at the time of
subcutaneous LMWH injection and 2 hrs, as well as 12 hrs after
LMWH (Figure S1). The heparin dose was adapted to patient
weight ranging from 40 mg to 100 mg enoxaparin subcutaneously
according to standard recommendations.
Serum sFlt-1 levels increase after heparin administration
sFlt-1 serum levels at baseline and at the time of heparin
administration were within the detectable range (median 6501 pg/
ml; 5829 pg/ml–8605.5 pg/ml, 25
th–75
th centile) and positively
correlated with the clinical diagnosis of preterm preeclampsia and
HELLP syndrome [5,8,9]. To assess alterations of sFlt-1 and PlGF
serum levels following LMWH administration we determined
relative changes in the interval ‘‘before enoxaparin’’, i.e. sFlt-1 and
PlGF serum values 2 hrs before treatment, at the time of
Prophylactic Heparin Alters sFlt-1 Distribution
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levels 2 hrs before and at the time of treatment revealed no
significant changes. Hence the difference between the first two
readings in any individual patient may serve as a valid internal
control. 2 hrs after the administration of LMWH sFlt-1 serum
levels increased by 26.0% on average (mean 1.26; p=0.0045)
(Fig. 1A). PlGF serum levels showed a more moderate increase of
15.4% (mean 1.154; p=0.0126) (Fig. 1B). Alterations in the sFlt-
1/PlGF ratio were consequently small and did not reach statistical
significance (mean 1,119; p=0.3031, Fig. 1C). Changes of sFlt-1,
PlGF and sFlt-1/PlGF for individual patients in the study are
shown in Figure S2A–C. 12 hours after administration of LMWH
serum sFlt-1 declined to almost the baseline levels (fold change
compared to baseline: mean 1.096; p=0.4594). To control for
effective application of LMWH we determined blood levels of anti-
activated Factor X activity. As expected, anti-Xa levels retraced
the amount of circulating LMWH (Figure S3) whereas no
significant difference was found in partial thromboplastin time
(mean fold change 1.08, p=0.0720).
Determination of PlGF is affected by low molecular
weight heparin in vitro
To control for assay artefacts, we added LMWH to pre-
treatment serum samples at a final concentration of 10 mg/l in
vitro and determined sFlt-1 and PlGF in the ElecsysH assay. The
heparin concentration of 10 mg/l used in the in vitro studies was
the result of a careful estimation of plasma levels. The volume of
distribution of heparin equals the plasma volume which contrib-
utes to approximately 5% of the total bodyweight. A person of
70 kg body weight will have approximately 3.5 liters of plasma.
The same patient would receive 35 mg enoxaparin (weight-
adapted dose). The resulting plasma concentration of enoxaparin
in this setting is approximately 10 mg/l. While sFlt-1 levels were
not significantly altered following LMWH application (mean
0.9865; SEM 0.046) (Fig. 2A), PlGF levels were significantly
increased (mean 2.084; SEM 0.309) (Fig. 2B). Consequently, the
sFlt-1/PlGF ratio appeared decreased. These findings ruled out
assay artefacts for the determination of sFlt-1 levels; however
heparin interfered with the PlGF assay. We therefore chose to
further pursue the in vivo effects of heparin on sFlt-1 levels.
The magnitude of sFlt-1 increase correlates positively
with initial sFlt-1 serum levels
The study population was quite diverse with regard to disease
severity and sFlt-1 levels. Some of the patients enrolled showed low
sFlt-1 serum levels of 3,000–4,000 pg/ml which were considered
borderline normal levels at their gestational age, while other
patients enrolled suffered from severe preeclampsia with sFlt-1
serum levels above 20,000 pg/ml. Interestingly, the magnitude of
sFlt-1 increase following LMWH administration seemed to depend
on the initial sFlt-1 serum level (Figure S2A). To determine a
potential correlation between baseline sFlt-1 levels and the amount
of increase after heparin we performed regression analysis using
the Spearman coefficient. The rate of increase correlated with
initial sFlt-1 levels with a Spearman correlation coefficient of
0.8273 (95%CI=0.4348 to 0.9556; p=0.0014) (Fig. 3).
Urinary sFlt-1 levels increase after heparin administration
sFlt-1 is detectable in the urine of preeclamptic patients [27].
Yet, the mechanism of renal sFlt-1 excretion has not been
explored. To test whether heparin affects the elimination of sFlt-1
from the circulation, we assessed renal excretion of sFlt-1 in
response to heparin treatment. Urine samples from before and
after LMWH administration were analysed using a sFlt-1 specific
ELISA. Patient #3 was lacking a timed urine sample two hours
after treatment and therefore excluded from this analysis.
Baseline levels of urinary sFtl-1 did not correlate with the extent
of proteinuria in individual patients (data not shown). After
heparin administration urinary levels of sFlt-1 increased in 7 out of
10 patients (Fig. 4A) compared to initial urinary sFlt-1 levels. Since
sFlt-1 is a positively charged protein with isoelectric point of
approximately 9.5 [28] and glomerular filtration largely depends
on the intact charge selectivity of the glomerular filter, we asked
whether urinary excretion of sFlt-1 in response to heparin is
dependent on the integrity of the glomerular filter. We then
performed subgroup analysis dividing the study population into
Table 1. Patient characteristics on admission.
Characteristics Pat_1 Pat_2 Pat_3 Pat_4 Pat_5 Pat_6 Pat_7 Pat_8 Pat_9 Pat_10 Pat_11
Maternal Age (yrs) 35 29 34 34 29 28 24 38 44 33 27
Gestational Age (weeks+days) 32+62 7 +13 8 +33 3 +43 5 +53 5 +23 2 +03 5 +13 7 +43 0 +43 1 +1
Systolic Blood Pressure (mmHg) 145 149 142 151 142 160 156 148 165 162 148
Diastolic Blood Pressure (mmHg) 97 102 95 92 92 102 101 97 101 92 101
Urine protein/creatinine ratio (mg/g) 234 ,0.04 741 632 241 1758 606 1889 196 338 15812
sFlt-1 plasma level (pg/ml) 8932 6501 3179 6427 2790 5339 24250 20514 6319 6596 8279
PlGF plasma level (pg/ml) 29.8 31.6 155.8 306.1 184.8 156.7 134.7 129.0 76.3 83.3 48,6
Hemoglobin (g/L) 11.5 13.0 10.7 10.1 11.0 11.0 11.4 12.6 13.3 13,4 12.1
Platelets (610
9/L) 69 209 203 286 184 185 150 148 237 300 263
Creatinine (mmol/L) 0.77 0.56 1.02 0.67 0.49 0.66 0.90 0.99 0.66 0.80 0.64
SGOT (U/L) 128 24 17 17 27 22 175 24 19 15 20
SGPT (U/L) 107 21 11 11 24 19 131 17 11 14 13
LDH (U/L) 327 182 203 179 177 268 260 223 184 178 226
Diagnosis HELLP IUGR, PIH DM1+late PE twins, PE PIH PE HELLP twins, PE PIH PE PE
Physical parameters and laboratory values were assessed upon admission in all patients. DM1=diabetes mellitus type 1; IUGR=intra uterine growth restriction;
PE=preeclampsia; PIH=pregnancy induced hypertension.
doi:10.1371/journal.pone.0085258.t001
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protein/g creatinine as a cut-off. Patients with relatively lower
proteinuria (Pat. #1, 2, 5, 9) and presumably preserved
glomerular filter showed a significant increase of urinary sFlt-1
excretion following heparin administration (mean 6.59; SEM
2.63). In striking contrast, the subgroup with a proteinuria
.300 mg/g only experienced a small increase in urinary sFlt-1
after heparin (mean 1.30; SEM 0.29) (Fig. 4B). No correlation
between urinary sFlt-1excretion and initial sFlt-1 serum levels was
found (Figure S4B). Addition of LMWH to serum and urine
samples did not affect measurements in the R&D assay (Figure S5).
Heparin alters charge-dependent binding properties of
sFlt-1 without affecting complex size
Knowing that renal elimination of sFlt-1 can be increased after
heparin therapy in patients with intact glomerular barrier, we set
out to further characterize the molecular basis of this effect in
biochemical studies. We tested the hypothesis that due to their
opposite charges, heparin liberates sFlt-1 from larger multi-
molecular complexes by charge dependent interaction. Mono-
meric sFlt-1 could then potentially be filtered via glomerular
barrier or be secreted into the proximal tubule. In order to
experimentally substantiate changes in complex size we employed
velocity gradient ultra-centrifugation on serum samples to separate
native complexes of serum proteins according to their density
before and after administration of heparin (Fig. 5A). After
separation of up to 22 fractions on SDS-PAGE and immunoblot
analysis using anti-Flt-1 specific antibody, sFlt-1 was detected in
the fractions 4–17 in samples of both before and after treatment.
This led us to infer that sFlt-1 complex size is not affected by
heparin administration.
In addition to size selectivity, selective exclusion of proteins from
the glomerular filtration is highly dependent on the molecular
charge [29–33]. As sFlt-1 is highly positively charged at
physiologic pH, it is likely to bind to the negative charge of the
glomerular basement membrane. LMWH may mask the positive
charge in the sFlt-1 molecule and, may facilitate glomerular
passage. To analyse changes in complex charge of sFlt-1 we
subjected serum samples before and after addition of 10 mg/l
enoxaparin to cation exchange chromatography. To compare
binding properties of sFlt-1 before and after the administration of
heparin we allowed binding of sFlt-1 to the resin at a
concentration of 110 mmol/L NaCl. Following elution with
increasing salt concentrations sFlt-1 was quantified in the flow
through and in the bound fractions using the Quantikine ELISA.
In untreated serum samples on average 70.14% of sFlt-1 bound to
the cation exchange matrix. After addition of enoxaparin at a
concentration 10 mg/l mimicking the in vivo situation after
LMWH treatment only 56.88% of the total sFlt-1 in the sample
bound to the column. These results were well complemented by
analysis of the sFlt-1 concentration in the flow through (Fig. 5B).
Discussion
Measurements of circulating angiogenic factors such as sFlt-1
and PlGF are rapidly evolving as tests for aid in diagnosis of
preeclampsia [6]. There is a large body of evidence that these
biomarkers may help not only in the early diagnosis of
preeclampsia, but also help with prediction of adverse maternal
and fetal outcomes [4,5,9,34–39]. Yet much has to be learned with
regard to influencing variables and characteristics of different
testing platforms. In addition, understanding the biochemical
properties and kinetics of sFlt-1 may allow us to identify novel
therapeutic targets for preeclampsia.
In this study, we sequentially measured blood and urine sFlt-1
levels before and after administration of LMWH for DVT-
prophylaxis in preeclamptic patients. Blood samples drawn 2 hrs
Figure 1. sFlt-1 and PlGF serum levels increase after the
administration of low molecular weight heparin. 2 hours after
the administration of enoxaparin sFlt-1 levels increase to 1.26 fold on
average (95% CI (interval before LMWH) 0,9627–1,040; 95% CI (interval
after LMWH) 1.103–1.418; p=0.0045) (A), PlGF levels increase to 1.15
fold on average (p=0.0126) (B), the resulting increase of sFlt-1/PlGF
ratio does not reach statistical significance (C).
doi:10.1371/journal.pone.0085258.g001
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control. We show that circulating sFlt-1 levels are increased
following administration of LMWH. Our findings not only support
previous reports by other groups in [25] but also reveal a positive
correlation between the initial sFlt-1 levels and the sFlt-1 increase
following LMWH. As has been reported previously, we also
observed that sFlt-1 concentrations declined to the baseline value
within 12 hrs after administration of LMWH suggesting that these
effects are temporally related to heparin therapy [15]. To exclude
the possibility that the changes in sFlt-1 levels may be due to assay
interference with heparin, we spiked low molecular weight heparin
to serum samples ex vivo and found no interference. However,
PlGF levels were elevated two fold following ex vivo heparin
treatment suggesting, that PlGF levels may not be reliably used in
patients receiving heparin therapy due to interference with the
assay. Taken together, we conclude that the effect of heparin on
sFlt-1 serum levels is highly dependent on the initial sFlt-1 levels
and the timing of heparin use. Our data has important implication
for using sFlt1 and PlGF assays in patients receiving heparin and
would advise against testing any sFlt-1 and PlGF levels until
heparin has completely cleared from the blood circulation.
We speculate that upon heparin treatment sFlt-1 bound to
heparan sulfate proteoglycans of the extracellular matrix is
mobilized into the circulation, as suggested by others [16].
Patients with high sFlt-1 levels at baseline bear a higher overall
sFlt-1 load, i.e. besides higher serum levels also the extracellular
matrix is highly saturated with sFlt-1 molecules. Administration of
exogenous heparin with its almost exclusive intravascular distri-
bution and its high negative charge adds additional sFlt-1 binding
sites to the intravascular compartment. More sFlt-1 bound to
extracellular matrix may translocate into the blood stream binding
to circulating heparin molecules which is detected on the
diagnostic assays. This is consistent with the observation of
displacement of sFlt-1 from pericellular glycosaminoglycans in
aortic arch - and umbilical vein explants as well as from human
placental villi in culture [15,16]. Binding of sFlt-1 to heparin is
most likely mediated by positively charged stretches of basophilic
aminoacids in the third and fourth immunoglobulin-like domain of
sFlt-1 [28,40].
Due to its high molecular weight and positive charge, sFlt-1 is
expected to be excluded from glomerular filtration. sFlt-1 has been
Figure 2. Addition of low molecular weight heparin in vitro affects PlGF measurements in the Elecsys Assay. Assessment of serum levels
after the administration of enoxaparin or vehicle in vitro shows only marginal differences for sFlt-1 (A+B). In contrast PlGF levels appear falsely high
after enoxaparin (C+D). Consequently the sFlt-1/PlGF ratio appears decreased (E+F).
doi:10.1371/journal.pone.0085258.g002
Figure 3. The rate of increase in serum sFlt-1 shows positive
correlation with the initial serum sFlt-1 levels. Regression analysis
of the alteration in serum sFlt-1 levels following enoxaparin (fold
change) and initial sFlt-1 serum levels yields positive correlation with
the Spearman correlation coefficient r=0.8273 (95%CI=0.4348 to
0.9556; p=0.0014).
doi:10.1371/journal.pone.0085258.g003
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endothelium with the negatively charged constituents of the
glomerular basement membrane where it may interfere with the
VEGF-dependent cross-talk between podocytes and endothelial
cells. This may very well explain the early and pronounced renal
phenotype of the multi-systemic disease of preeclampsia. Never-
theless, there are reports that sFlt-1 can be detected in the urine
during active preeclampsia and may serve as diagnostic marker
[27,41]. In our study, we could confirm the previously published
range of sFlt-1 levels in urine samples of patients with preeclamp-
sia and HELLP syndrome. However, we did not find any
correlation between serum and urine levels of sFlt-1. Surprisingly,
we found a heterogenous response of urinary sFlt-1 levels to
heparin treatment. Subgroup analysis revealed that patients with
lower or absent proteinuria and presumably intact glomerular
filter responded with more dramatic urinary excretion of sFlt-1
following heparin administration. In patients with significant
glomerular damage and proteinuria this effect is lost. In the latter
patients, serum sFlt-1 is detected at much higher levels. Although
we cannot rule out de novo synthesis of sFlt-1 in tubular or
glomerular cells or tubular secretion, this data strongly suggests
that urinary excretion of sFlt-1 is dependent on molecular charge.
sFlt-1 filtration is enhanced after heparin in those patients with an
intact glomerular filter. In patients with a compromised glomer-
ular filtration barrier charge selectivity is lost and heparin
administration will not lead to an increment of filtered sFlt-1.
Interestingly, sFlt-1 excretion and the response to LMWH did not
correlate with initial serum sFlt-1 levels.
To understand the underlying mechanism of increased serum
levels and altered renal elimination of sFlt-1 following heparin we
addressed the question whether heparin could influence size and/
or molecular charge of the sFlt-1 protein complex.
Our biochemical experiments showed that heparin treatment
did not affect the size of the sFlt-1 protein complex. This excluded
the possibility that heparin treatment led to the disassembly of
larger multi-molecular sFlt-1 complexes. Employing cation
exchange chromatography on serum samples before and after
addition of LMWH we could show that heparin reduces the
affinity of sFlt-1 to negatively charged surfaces. This suggests that
LMWH treatment in vivo weakens the binding of sFlt-1 to fixed
negative charges of the glomerular basement membrane and thus
potentially facilitates glomerular filtration of sFlt-1.
Figure 4. Administration of low molecular weight heparin results in elevated urinary sFlt-1 levels. Urinary sFlt-1 levels (pg/mg Crea) are
increased 2 hours after administration of enoxaparin in 7 out of 10 patients (A). Subgroup analysis according to proteinuria at presentation (cut-off of
300 mg protein/g creatinine) reveals that patients with a proteinuria ,300 mg/g respond with a significantly higher increase of urinary sFlt-1 after
heparin treatment (p=0.0365) (B).
doi:10.1371/journal.pone.0085258.g004
Figure 5. Heparin does not affect sFlt-1 protein complex size but interferes with sFlt-1 binding to negatively charged surfaces.
Serum samples before and after low molecular weight heparin treatment were subjected to velocity gradient centrifugation. Western blotting of
fractions 5–18 was performed using Flt-1 specific antibody (A). Serum samples before and after addition of 10 mg/l enoxaparin were subjected to
cation exchange chromatography. In non-treated serum samples 70.14% of sFlt-1 binds to the column, whereas the remaining 29. 86% are found in
the flow through. After enoxaparin treatment only 56.88% of sFlt-1 is bound and 43.11% appear in the flow through (p=0.0386) (B).
doi:10.1371/journal.pone.0085258.g005
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is a general problem in studies on preeclamptic patients recruited
during in-patient setting. Once these patients require hospital
admission, rapid deterioration in the medical condition or
imminent delivery impedes enrolment into clinical studies.
Therefore cooperation of multiple centers and out-patient clinics
with similar treatment protocols is warranted when studying
patients with preeclampsia. In addition our biochemical studies
can only provide indirect proof of an alteration of sFlt-1 complex
charge. Further biochemical and in vivo studies are warranted to
establish that renal elimination of sFlt-1 indeed depends on
protein-charge. Different modifications of recombinant sFlt-1 with
alterations of charged residues should be generated to study sFlt-1
biodistribution and renal excretion e.g. in a mouse model.
Employing angiogenic factors like sFlt-1 and PlGF for clinical
use for the prediction and diagnosis of preeclampsia as well as
validating therapeutic approaches warrants complete understand-
ing of the characteristics and influencing variables of those factors
in vivo and in vitro.
In summary, we conclude from our observations that (i) acute
administration of low molecular weight heparin leads to increased
sFlt-1 serum levels (ii) Heparin bound sFlt-1 may be more easily
eliminated into the urine by the kidney. The source of increased
circulating sFlt1 following low molecular weight heparin therapy is
unknown. Whether enhanced urinary excretion of sFlt-1 following
heparin therapy is a result of glomerular filtration or tubular
secretion is also yet to be determined.
Supporting Information
Figure S1 Study scheme. Blood samples (red triangles) were
drawn 2 hours prior and directly before sub cutaneous injection of
low molecular weight heparin (enoxaparin-sodium). In succession
blood was obtained 2 hours and 12 hours after heparin admin-
istration.
(TIF)
Figure S2 Alterations of serum sFlt-1, serum PlGF and sFlt-1/
PlGF ratio in individual patients. sFlt-1, PlGF and sFlt-1/PlGF
was determined in the serum of the study patients 2 hours prior,
directly before and 2 hours after enoxaparin treatment. The
figures shows fold change of sFlt-1 (A), PlGF (B) and sFlt-1/PlGF
(C) in the interval before and after treatment.
(TIF)
Figure S3 Anti-activated Factor X levels serve as a control for
the administration of low molecular weight heparin. Anti-Xa was
determined with all main blood draws.
(TIF)
Figure S4 Alterations of urinary sFlt-1 in individual patients.
sFlt-1 was determined in the urine of 10 out of 11 study patients
before and after enoxaparin treatment and normalized to urinary
creatinine levels. (A) shows fold change of urinary sFlt-1/Crea. No
correlation was found between urinary sFlt-1/Crea and initial sFlt-
1 serum levels (B).
(TIF)
Figure S5 Addition of low molecular weight heparin in vitro does
not affect sFlt-1 measurements using the R&D ELISA kit.
Assessment of serum levels with the R&D ELISA after the
administration of enoxaparin or vehicle in vitro shows no significant
differences in sFlt-1 levels (A and B). There is also no significant
difference seen in urinary sFlt1 levels after administration of
enoxaparin or vehicle in vitro (C and D).
(TIF)
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